Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

r placebo (n=118). Significantly more patients in the desvenlafaxine succinate group responded to treatment compared with the placebo group (51 percent vs. 32 percent, respectively) at the final study evaluation. When individual items from the HAM-D17 were analyzed, desvenlafaxine succinate patients experienced a statistically significant improvement in depressed mood, psychic anxiety, general somatic symptoms and suicidal thoughts. Treatment-emergent adverse events reported in this study were consistent with the SNRI class and included nausea, dry mouth, insomnia, somnolence, sweating, anorexia (loss of appetite), tremor and impotence.

About Desvenlafaxine

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for adult men and women with MDD. Wyeth submitted a New Drug Application (NDA) for MDD on December 22, 2005. The Company also has filed an NDA for vasomotor symptoms (VMS) associated with menopause and expects a U.S. Food and Drug Administration (FDA) action letter in the third quarter of 2007. If approved, desvenlafaxine will be the first and only non-hormonal medicine for the treatment of VMS associated with menopause. Wyeth is a leader in both neuroscience and women's health care.

Wyeth discovered and developed the first SNRI approved by the FDA, which currently is the most widely used antidepressant in the world. Desvenlafaxine represents Wyeth's latest efforts and continued commitment to developing therapies to help improve the lives of patients suffering from mental health disorders.

According to a large depression trial funded by the National Institute of Mental Health, only 28 percent of patients with depression achieved remission with initial antidepressant treatment. This leaves a large percentage of patients still suffering from depression. Clearly, additional medicines are needed for treating MDD.

About Antidepressants

Antidepressants increased the risk of s
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/2/2014)... CARPINTERIA, Calif. , Sept. 2, 2014 ... assessments and penetration testing services, today released an IT ... industry. "Today,s healthcare CEOs are presiding over ... industry," said Daniel W. Berger , Redspin,s President ... help CEO,s and their Boards of Directors understand why ...
(Date:9/2/2014)... BEIJING , Sept. 2, 2014  Sinovac Biotech Ltd. ... products in China , today announced that ... in September: , Morgan Stanley Global Healthcare Conference, ... September 9 and 10, 2014. , Morgan Stanley Asia ... Hotel on September 11, 2014. , Aegis Healthcare & ...
(Date:9/2/2014)... Sept. 2, 2014  Drug delivery technologies that improve ... part of the entire drug development process. Pharmaceutical ... new vaccine delivery technologies in a bid to ... delivery procedures. New analysis from Frost ... the needle-free delivery sector currently makes up a ...
Breaking Medicine Technology:Sinovac to Participate in Upcoming Investor Conferences 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 MyRounding, the ... care, has been selected from a group of over ... the 2014 PrIME Digital Health Challenge. The competition will ... another, Tuesday, Sept. 9th at the CSU Denver Atrium ... MyRounding is based in Denver, Colo. The cloud-based, SaaS ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of Medicare ... to announce that it has released a special report ... 2015 Hospital Inpatient Prospective Payment System (IPPS) final rule ... Services. , “Hospitals are facing decreased Medicare reimbursements in ... BESLER’s President and Chief Executive Officer. “We are happy ...
(Date:9/2/2014)... September 02, 2014 “Is there an ... question that millions of people ask. Diagnosing and curing ... patients and their families or treatment partners. The diagnostic ... its distinct similarities to other skin conditions such as: ... bites, eczema, varicella and many others. Scabies is ...
(Date:9/2/2014)... 02, 2014 Michigan’s health care landscape ... Act and the Healthy Michigan Plan. Throughout these changes, ... a trusted funding resource for under-served individuals. Federal and ... or underinsured women between the ages of 50 and ... percent of the federal poverty level. , ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
Breaking Medicine News(10 mins):Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2
... (sildenafil) can improve exercise capacity and functional ability in ... high pressure in the blood vessels that enter the ... report by Reuters, the findings, which appear in The ... study of 278 patients who were randomly selected to ...
... to stress during early life can lead to an ... adolescence.// It therefore, highlights the need for a counseling ... of growth. ,Several studies have established a ... with an increased risk of developing attachment disorders. These ...
... Death Syndrome (SIDS) has found out that nearly all cases ... a male sex hormone. //The levels are considerably higher in ... who have died suddenly from other causes. ,Researchers ... collected from 169 infants who had died of SIDS and ...
... findings were published by chemists at Harvard University, who ... they trigger could hold the key to oncogenesis,// the ... arises when an oncoprotien, a protein known to cause ... development of cancer, 'We present the hypothesis that an ...
... Research Institute have now found out that heart disease ... the thyroid gland.// Aggressive treatment of hypothyroidism and borderline ... diseases to a significant extent. ,The study has ... can be extrapolated to human beings as well. The ...
... of the National Cancer Institute conducted a meta-analysis of ... and the prevalence and associated mortality from colorectal cancer. ... of the Karolinska Institute in Stockholm, and colleagues. The ... at a 30 percent risk of developing colorectal cancer ...
Cached Medicine News:Health News:Teenage Mental Problems Could Be The Result Of Stress During Early Life 2Health News:Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: